Zenocutuzumab-independent BET inhibitor ZEN-3694 — Investigational Agent
BET Inhibitor · Phase 2 · Zenith Epigenetics
Mechanism of Action
An oral small-molecule inhibitor of BET bromodomain proteins (BRD2/3/4) that disrupts transcription of oncogenic drivers such as MYC and AR-target genes, and can restore sensitivity to PARP and androgen-axis therapies.
Investigational Indications
- Metastatic castration-resistant prostate cancer
- Ovarian and other solid tumors
- NUT carcinoma